Phase I/II clinical trial to assess safety and efficacy of intratumoral and subcutaneous injection of HVJ-E in castration-resistant prostate cancer patients

Published on May 12, 2017in Cancer Gene Therapy4.534
· DOI :10.1038/CGT.2017.15
Kazutoshi Fujita30
Estimated H-index: 30
(Osaka University),
Yasutomo Nakai21
Estimated H-index: 21
(Osaka University)
+ 9 AuthorsNorio Nonomura55
Estimated H-index: 55
(Osaka University)
Inactivated Sendai virus particles (hemagglutinating virus of Japan envelope (HVJ-E)) have a novel antitumor effect: HVJ-E fused to prostate cancer cells via cell surface receptor causes apoptosis of prostate cancer cells in vitro and in vivo. HVJ-E also induces antitumor immunity by activating natural killer (NK) cells and cytotoxic T cells and suppressing regulatory T cells in vivo. We conducted an open-label, single-arm, phase I/II clinical trial in patients with castration-resistant prostate cancer (CRPC) to determine the safety and efficacy of intratumoral and subcutaneous injection of HVJ-E. Patients with CRPC who were docetaxel-resistant or could not receive docetaxel treatment were eligible. HVJ-E was injected directly into the prostate on day 1 and subcutaneously on days 5, 8 and 12 in two 28-day treatment cycles using a 3+3 dose-escalation design. The primary end points were to evaluate safety and tolerability of HVJ-E. The secondary end points were to analyze tumor immunity and antitumor effect. The study is registered at UMIN Clinical Trials Registry, number UMIN000006142. Seven patients were enrolled, and six patients received HVJ-E. Grade 2 or 3 adverse events (Common Terminology Criteria for Adverse Events Ver. 4.0) were urinary retention and lymphopenia from which the patients recovered spontaneously. No Grade 4 adverse events were observed. Radiographically, three patients had stable disease in the low-dose group, and one patient had stable disease and two had progressive disease in the high-dose group. The prostate-specific antigen (PSA) declined from 14 to 1.9 ng ml−1 in one patient in the low-dose group after two cycles of HVJ-E treatment, and the PSA response rate was 16.6%. NK cell activity was elevated from day 12 to day 28 after HVJ-E administration, whereas serum interleukin-6, interferon (IFN)-α, IFN-β and IFN-γ levels were not affected by HVJ-E treatment. Intratumoral and subcutaneous injections of HVJ-E are feasible and PSA response was observed in a subgroup of CRPC patients.
📖 Papers frequently viewed together
2 Citations
21 Citations
#1Hiromi Kumon (Okayama University)H-Index: 61
#2Yuichi Ariyoshi (Okayama University)H-Index: 6
Last. Yasutomo Nasu (Okayama University)H-Index: 39
view all 9 authors...
Adenovirus vector carrying REIC/DKK-3 gene: neoadjuvant intraprostatic injection for high-risk localized prostate cancer undergoing radical prostatectomy
17 CitationsSource
Incorporation of docetaxel into metastatic castration-sensitive prostate cancer treatment has added a new treatment option to a disease state that had previously not seen change for decades. Early attempts of a chemo-hormonal approach for castration-sensitive prostate cancer were not successful. With the demonstration of survival benefits using docetaxel in patients with metastatic castration-resistant prostate cancer, this encouraged continued research with docetaxel given earlier in the diseas...
11 CitationsSource
#1Kazuhiro Yoshimura (Kindai University)H-Index: 12
#2Takafumi Minami (Kindai University)H-Index: 9
Last. Hirotsugu Uemura (Kindai University)H-Index: 36
view all 9 authors...
Abstract Background It is well known that the prognosis of castration-resistant prostate cancer (CRPC) is poor, and several immunotherapeutic strategies have been applied to the clinical trials. Research on immunotherapy has been of special interest for the treatment of CRPC for years. Objective To evaluate the safety of personalized peptide vaccine (PPV) immunotherapy and its clinical outcomes. Design, setting, and participants A phase 2 randomized controlled trial of PPV immunotherapy with low...
53 CitationsSource
#1Hiromi Kumon (Okayama University)H-Index: 61
#2Katsumi Sasaki (Okayama University)H-Index: 15
Last. Yasutomo Nasu (Okayama University)H-Index: 39
view all 10 authors...
A 63-year-old man with metastatic castration-resistant prostate cancer (CRPC) was successfully treated for two years with in situ gene therapy using an adenovirus vector carrying the human REIC/Dkk-3 gene (Ad-REIC), following chemotherapy. Ad-REIC mediates simultaneous induction of cancer-selective apoptosis and augmentation of antitumor immunity, and a Phase I/IIa clinical study on Ad-REIC has been conducted at Okayama University Hospital since January 2011. At the time of enrollment in Decembe...
19 CitationsSource
#1Michael T. Schweizer (Johns Hopkins University)H-Index: 25
#2Charles G. Drake (Johns Hopkins University)H-Index: 89
Since the approval of sipuleucel-T for men with metastatic castrate resistant prostate cancer in 2010, great strides in the development of anti-cancer immunotherapies have been made. Current drug development in this area has focused primarily on antigen-specific (i.e. cancer vaccines and antibody based therapies) or checkpoint inhibitor therapies, with the checkpoint inhibitors perhaps gaining the most attention as of late. Indeed, drugs blocking the inhibitory signal generated by the engagement...
49 CitationsSource
#1Susan F. Slovin (MSK: Memorial Sloan Kettering Cancer Center)H-Index: 54
#2Celestia S. Higano (UW: University of Washington)H-Index: 86
Last. Tomasz M. Beer (OHSU: Oregon Health & Science University)H-Index: 70
view all 11 authors...
Background This phase I/II study in patients with metastatic castration-resistant prostate cancer (mCRPC) explored ipilimumab as monotherapy and in combination with radiotherapy, based on the preclinical evidence of synergistic antitumor activity between anti-CTLA-4 antibody and radiotherapy.
407 CitationsSource
#1Taeko Matsushima-Miyagi (Osaka University)H-Index: 1
#2Koji Hatano (Osaka University)H-Index: 13
Last. Yasufumi Kaneda (Osaka University)H-Index: 108
view all 8 authors...
Purpose: The treatment of cancer with oncolytic viruses primarily depends on the selective viral replication in cancer cells. However, a replication-incompetent hemagglutinating virus of Japan (HVJ; Sendai virus) envelope (HVJ-E) suppresses the growth of human cancer cells as effectively as replication-competent live HVJ without producing toxic effects in nonmalignant cells. Here, we analyze the molecular mechanism of the oncolytic activity of HVJ-E. Experimental Design: The molecules responsibl...
65 CitationsSource
#1Suzanne L. Topalian (Johns Hopkins University)H-Index: 99
#2F. Stephen Hodi (Harvard University)H-Index: 126
Last. Mario Sznol (Yale University)H-Index: 81
view all 30 authors...
Background Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. Methods We enrolled patients with advanced melanoma, non–small-cell lung cancer, castrationresistant prostate cancer, or renal-cell or colorectal cancer to receive anti–PD-1 antibody at a dose of 0.1 to 10.0 mg per kilogram of body weight every 2 weeks. Response was as...
8,402 CitationsSource
#1Koji Hatano (Osaka University)H-Index: 13
#2Yasuhide MiyamotoH-Index: 22
Last. Yasufumi Kaneda (Osaka University)H-Index: 108
view all 7 authors...
The expression of gangliosides is often associated with cancer progression. Sialyltransferases have received much attention in terms of their relationship with cancer because they modulate the expression of gangliosides. We previously demonstrated that GD1a production was high in castration-resistant prostate cancer cell lines, PC3 and DU145, mainly due to their high expression of β-galactoside α2,3-sialyltransferase (ST3Gal) II (not ST3Gal I), and the expression of both ST3Gals was regulated by...
25 CitationsSource
#1Koji Hatano (Osaka University)H-Index: 13
#2Yasuhide MiyamotoH-Index: 22
Last. Yasufumi Kaneda (Osaka University)H-Index: 108
view all 4 authors...
Gangliosides are sialic acid–containing glycosphingolipids that are associated with tumor malignancy and progression. Among the enzymes required for the production of gangliosides, sialyltransferases have received much attention in terms of their relationship with cancer. In our previous report, ganglioside GD1a and sialyl paragloboside (SPG), a neolacto-series ganglioside, were much more abundant in PC3 and DU145 cells, castration-resistant prostate cancer cells, as compared with hormone-sensit...
33 CitationsSource
Cited By12
#1Dominik Witzigmann (University of Basel)H-Index: 16
#2Philip Grossen (University of Basel)H-Index: 8
Last. Jörg Huwyler (University of Basel)H-Index: 49
view all 18 authors...
Abstract Hepatocellular carcinoma (HCC) is related to increasing incidence rates and poor clinical outcomes due to lack of efficient treatment options and emerging resistance mechanisms. The aim of the present study is to exploit a non-viral gene therapy enabling the expression of the parvovirus-derived oncotoxic protein NS1 in HCC. This anticancer protein interacts with different cellular kinases mediating a multimodal host-cell death. Lipoplexes (LPX) designed to deliver a DNA expression plasm...
#1Yi Chun Pan (Osaka University)
#2Tomoyuki Nishikawa (Osaka University)H-Index: 10
Last. Yasufumi Kaneda (Osaka University)H-Index: 108
view all 5 authors...
Abstract Breast cancer has a high risk of metastasis; however, no effective treatment has been established. We developed a novel immunotherapy for breast cancer to enhance cytotoxic T lymphocytes against cancer cells using N1 type neutrophils with anti-tumor properties. For this purpose, we combined CXCL2 (CXC chemokine ligand 2) plasmid DNA with inactivated Sendai virus (hemagglutinating virus of Japan)-envelope (HVJ-E). The combination of CXCL2 DNA and HVJ-E (C/H) suppressed the growth of muri...
1 CitationsSource
#2Yasushi ShintaniH-Index: 28
Last. Meinoshin OkumuraH-Index: 2
view all 3 authors...
#1Sandra Iurescia (National Research Council)H-Index: 13
#2Daniela Fioretti (National Research Council)H-Index: 14
Last. Monica Rinaldi (National Research Council)H-Index: 25
view all 3 authors...
Over the last 15 years, the ability to harness a patient's own immune system has led to significant progress in cancer therapy. For instance, immunotherapeutic strategies, including checkpoint inhibitors or adoptive cell therapy using chimeric antigen receptor T-cell (CAR-T), are specifically aimed at enhancing adaptive anti-tumour immunity. Several research groups demonstrated that adaptive anti-tumour immunity is highly sustained by innate immune responses. Host innate immunity provides the fi...
2 CitationsSource
#1Kazutoshi Fujita (Osaka University)H-Index: 30
#2Taigo Kato (Osaka University)H-Index: 10
Last. Norio Nonomura (Osaka University)H-Index: 55
view all 13 authors...
Inactivated hemagglutinating virus of Japan envelope (HVJ-E) has an antitumor effect and tumor immunity. We undertook an open-label, phase I, dose-escalation study in patients with castration-resistant prostate cancer (CRPC) to determine the safety and efficacy of intratumoral and s.c. injection of HVJ-E (GEN0101). Patients with CRPC, who were resistant to or unable to receive standard of care, were included. GEN0101 was injected directly into the prostate and s.c. in two 28-day treatment cycles...
2 CitationsSource
#1Eiji Kiyohara (Osaka University)H-Index: 9
#2Atsushi Tanemura (Osaka University)H-Index: 23
Last. Ichiro Katayama (Osaka University)H-Index: 58
view all 14 authors...
Hemagglutinating virus of Japan (HVJ; Sendai virus) is an RNA virus that has cell fusion activity. HVJ-envelope (HVJ-E) is a UV-irradiated HVJ particle that loses viral replication and protein synthesis activity but retains cell fusion activity. We recently reported that HVJ-E has antitumor effects on several types of tumors. Here, we describe the results of a first-in-human phase I/IIa study in patients with advanced melanoma, receiving intratumoral administration of HVJ-E. The primary aim was ...
3 CitationsSource
#1Satoru Taguchi (Kyorin University)H-Index: 13
#2Hiroshi Fukuhara (Kyorin University)H-Index: 25
Last. Tomoki Todo (UTokyo: University of Tokyo)H-Index: 34
view all 3 authors...
: Oncolytic virus therapy is a promising new option for cancer. It utilizes genetically engineered or naturally occurring viruses that selectively replicate in and kill cancer cells without harming normal cells. T-VEC (talimogene laherparepvec), a second-generation oncolytic herpes simplex virus type 1, was approved by the US Food and Drug Administration for the treatment of inoperable melanoma in 2015 and subsequently approved in Europe in 2016. Other oncolytic viruses using different parental ...
15 CitationsSource
#1Sumimasa Nagai (UTokyo: University of Tokyo)H-Index: 7
#2Daisuke Sugiyama (Kyushu University)H-Index: 21
Abstract Purpose In Japan, gene therapy and cellular therapy are categorized as regenerative medicine products based on the Pharmaceuticals and Medical Devices Law that was implemented in 2014. In this new law, regenerative medicine products were newly defined, and a conditional and term-limited approval system for regenerative medicine products was instituted. In addition, the Ministry of Health, Labour and Welfare instituted the SAKIGAKE (meaning pioneer or forerunner in Japanese) designation ...
2 CitationsSource
#1Marat LernerH-Index: 14
#2Georgy Mikhaylov (Jožef Stefan Institute)H-Index: 7
Last. Olga VasiljevaH-Index: 19
view all 11 authors...
Owing to their unique physicochemical properties, nanomaterials have become a focus of multidisciplinary research efforts including investigations of their interactions with tumor cells and stromal compartment of tumor microenvironment (TME) toward the development of next-generation anticancer therapies. Here, we report that agglomerates of radially assembled Al hydroxide crumpled nanosheets exhibit anticancer activity due to their selective adsorption properties and positive charge. This effect...
16 CitationsSource
#1Sandra Iurescia (National Research Council)H-Index: 13
#2Daniela Fioretti (National Research Council)H-Index: 14
Last. Monica Rinaldi (National Research Council)H-Index: 25
view all 3 authors...
The innate immune system provides the first line of defense against pathogen infection though also influences pathways involved in cancer immunosurveillance. The innate immune system relies on a limited set of germ line-encoded sensors termed pattern recognition receptors (PRRs), signaling proteins and immune response factors. Cytosolic receptors mediate recognition of danger damage-associated molecular patterns (DAMPs) signals. Once activated, these sensors trigger multiple signaling cascades, ...
61 CitationsSource